
WB analysis of various samples using GTX85102 B-Raf antibody. Dilution : 0.5microg/mL Loading : 15microg of lysates per lane
B-Raf antibody
GTX85102
Overview
- SupplierGeneTex
- Product NameB-Raf antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 0.5-2 microg/mL. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- Concentration1 mg/ml
- FormulationLiquid
- Gene ID673
- Target nameBRAF
- Target descriptionB-Raf proto-oncogene, serine/threonine kinase
- Target synonyms94 kDa B-raf protein; B-raf; B-Raf proto-oncogene serine/threonine-protein kinase (p94); B-Raf serine/threonine-protein; BRAF1; B-RAF1; murine sarcoma viral (v-raf) oncogene homolog B1; NS7; proto-oncogene B-Raf; RAFB1; serine/threonine-protein kinase B-raf; v-raf murine sarcoma viral oncogene homolog B; v-raf murine sarcoma viral oncogene homolog B1
- Protein IDP15056
- Protein NameSerine/threonine-protein kinase B-raf
- Scientific DescriptionB-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways interact with each other to regulate growth and in some cases tumorigenesis. Mutations in B-raf have been associated with several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung, leading to speculation on the possibility of B-raf as a therapeutic target for treating cancers. Mutations in this gene have also been associated with cardiofaciocutaneous syndrome (CFCS), a disease characterized by heart defects, mental retardation and a distinctive facial appearance.
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203